Jefferies Financial Group Inc. Eli Lilly & CO Call Options Transaction History

Jefferies Financial Group Inc.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 13, 2024	SELL	$525.19 - $619.13 $4.36 Million - $5.14 Million	-8,300 Reduced 17.36%	39,500 $23 Million
Q3 2023 Nov 14, 2023	SELL	$434.7 - $599.3 $2.52 Million - $3.48 Million	-5,800 Reduced 10.82%	47,800 $25.7 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $4.95 Million - $6.61 Million	14,100 Added 35.7%	53,600 $25.1 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $8.2 Million - $9.63 Million	-26,400 Reduced 40.06%	39,500 $13.6 Million
Q4 2022 Sep 21, 2023	BUY	$321.55 - $374.67 $3.96 Million - $4.61 Million	12,300 Added 22.95%	65,900 $24.1 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $21.2 Million - $24.7 Million	65,900 New	65,900 $24.1 Million

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $749B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.